Posted by Medivizor on Feb 28, 2021 in Diabetes mellitus | In a nutshell This review focused on the effect of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on heart failure hospitalization in patients with type 2 diabetes (T2D). This analysis showed that
From before the coronavirus disease 2019 (COVID-19) pandemic, the effect of dipeptidyl peptidase 4 inhibitors (DPP-4i) on respiratory infections (RI) remains unclear. The meta-analysis of Yang et al. (1) specifically assessed the risk of infection with DPP-4i. However, cardiovascular outcomes
Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults Elisabetta Patorno, Ajinkya Pawar, Lily G. Bessette, Dae H. Kim, Chintan Dave, Robert J. Glynn, Medha N. Munshi, Sebastian Schneeweiss, Deborah J.
1.Centers for Disease Control and Prevention. National Diabetes Statistical Report. Centers for Disease Control and Prevention https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf (2020).2.Koye, D. N., Magliano, D. J., Nelson, R. G. & Pavkov, M. E. The global epidemiology of diabetes and kidney disease. Adv. Chronic
How SGLT2 Inhibitors Affect Risk of Death A recent study that aimed to review and assess all the current evidence regarding SGLT2 inhibitors and their impact on death from all causes in diabetes patients found that overall, this class of
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are second- to third-line antidiabetes drugs that have been shown to have cardiovascular benefits. However, in premarketing trials of the SGLT2 inhibitor dapagliflozin, there were numerical imbalances in breast cancer events compared with placebo; all
Posted by Medivizor on Dec 6, 2020 in Diabetes mellitus | In a nutshell This study used real-world data to compare SGLT-2 inhibitors versus other medications for patients with type 2 diabetes (T2D). It found that SGLT-2 inhibitors led to
Posted by Medivizor on Nov 29, 2020 in Diabetes mellitus | In a nutshell This review looked at how SGTL2 inhibitors with or without metformin (Glucophage) affect heart and kidney health for patients with type 2 diabetes (T2D). It found